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Tanshinone IIA is one of the active principles in danshen (Salvia miltiorrhiza Bge) widely used in treatment of cardiovascular
disorders. We investigated the eﬀect of danshen or tanshinone IIA on blood pressure and its possible mechanisms. An i.p. injection
of danshen at 10mgkg−1 signiﬁcantly lowered systolic blood pressure (SBP) of spontaneously hypertensive rats (SHRs) but failed
to modify the SBP in normotensive Wistar-Kyoto rats (WKY). Oral administration of tanshinone IIA also decreased SBP in SHR
but not in WKY. Tanshinone IIA produced a concentration-dependent relaxation in isolated SHR aortic rings precontracted with
phenylephrine(10nmoll−1)orpotassiumchloride(KCl)(40mmoll−1).TherelaxingeﬀectoftanshinoneIIAontoniccontraction
of phenylephrine in isolated aortic rings without endothelium remained produced. Glibenclamide at concentration suﬃcient to
block adenosine triphosphatase (ATP)-sensitive potassium (K+) channel attenuated this tanshinone IIA-induced relaxation that
was not inﬂuenced by other inhibitors. We further investigated the eﬀect of tanshinone IIA on the changes of intracellular calcium
concentration ([Ca
2+]i) in cultured aortic smooth muscle (A7r5) cells using fura-2 as indicator. Tanshinone IIA decreased [Ca
2+]i
elicited by phenylephrine (10nmoll−1) or KCl (40mmoll−1) in a concentration-dependent manner; glibenclamide, but not other
inhibitors for K+ channel, abated this eﬀect. Our results suggest that tanshinone IIA acts as an active principle of danshen showing
vasodilation through ATP-sensitive K+ channel to lower [Ca
2+]i.
1.Introduction
Danshen, the dry root and rhizome of Salvia miltiorrhiza
Bge (Labiatae), is one of the popular herbs used in China
and the neighboring countries. This herb is widely applied
in traditional Chinese medicine for promotion of blood ﬂow
to overcome blood stasis and to resolve abscesses [1]. Many
clinical studies showed that Danshen and its preparations
are eﬀective for the treatment of coronary artery diseases,
angina pectoris, myocardial infarction, cerebrovascular dis-
eases, various types of hepatitis and chronic renal failure
[1–3]. In addition to the protection of cardiac muscle during
angioplasty or heart transplantation, Danshen has also
been recommended for treatments of menstrual disorder,
insomnia as well as inﬂammation [4, 5].
Danshen and its medicinal products are widely used in
Asian area for supporting cardiovascular function; evalua-
tion of the active constituents in this herb is essential to
ensure the eﬃciency of medication. Studies showed that this
herb contains several pharmacologically active compounds,
especially the diterpene diketones known as tanshinones [6].
This major active ingredient of Danshen is reported to work
as a vasodilator, causing blood vessels to relax and increase
blood circulation. Also, it has the ability to inhibit platelet
aggregation, thereby reducing the risk of arteriosclerosis,
strokeandheartattack[5].Tanshinonesseemtobetheactive
ingredients of Danshen for cardioprotective eﬀect.
Danshenhasbeenmentionedtoinhibitangiotensin-con-
verting enzyme, an essential regulatory enzyme of rennin-
angiotensin system, for lowering blood pressure [7]. In fact,2 Evidence-Based Complementary and Alternative Medicine
the membrane potential is a major determinant of vascular
tone; changes in potassium (K+) channel activity is respon-
sible for the reduction of intracellular calcium ion concen-
trations ([Ca2+]i) to produce vasodilatation [8]. However,
the eﬀect of tanshinone on vascular tone involved in the
changes of K+ conductance to regulate Ca2+ mobilization is
still not established. Thus, the main aim of this study is to
evaluate the eﬀect of tanshinone IIA, one of the tanshinones,
on blood pressure in rats with spontaneous hypertension
and to characterize the eﬀect of tanshinone IIA on vascular
tone, using speciﬁc blockers of K+ channel to investigate
the role of this channel in spontaneously hypertensive rat
(SHR)-isolated aortic rings strips and cultured A7r5 vascular
smooth muscle cells.
2. Methods
2.1. Materials. Danshen (voucher 0425) and tanshinone
IIA with the purity of 98% was gifted from Prof. De-Yu
Xu (Department of Pharmacology, College of Medicine,
Nanjin University, Nanjin City, China). Acetylcholine, l-
phenylephrine, potassium chloride, glibenclamide, apamin,
charybdotoxin, barium chloride and 4-aminopyridine were
obtained from Sigma-Aldrich, Inc. (St. Louis, MO, USA).
Dulbecco’s modiﬁed Eagle’s medium (DMEM) was pur-
chased from GIBCO BRL (Gaithersburg, MD). Fura-2
acetoxymethyl ester (fura-2) was from Molecular Probes Inc.
(Eugene, OR, USA). All other reagents were obtained from
standard sources.
2.2. Experimental Animals. We obtained 10-week-old male
rats with SHR and age-matched male Wistar-Kyoto rats
(WKY) from National Animal Center (Taipei, Taiwan) to
keep in our animal center. Also, the male Wistar rats at
same age from our animal center were employed. They were
maintained in a temperature-controlled room (25
◦C ± 1)
under a cycle of 12h of light (beginning at 6:00A.M.) and
12h of darkness. All rats were given water and fed standard
chow (Purina Mills, LLC, St Louis, MO, USA) ad libitum.
All animal-handling procedures were performed according
to the Guide for the Care and Use of Laboratory Animals of
the National Institutes of Health as well as the guidelines of
the Animal Welfare Act.
2.3. Measurement of Blood Pressure in Conscious Rats. The
powder of danshen and compound of tanshinone IIA were
dissolved in alcoholic solution (90%) and prepared with
distilledwatercontaining0.9%sodiumchlorideimmediately
before use. Danshen solution at the indicated dose was given
byanintraperitoneal(i.p.)injectionintorats.Anothergroup
of rats were treated by an oral administration of tanshinone
IIA solution at the desired dose. Control rats received similar
administration of vehicle at same volume as that used in the
treated rats.
Systolic blood pressure (SBP) in conscious rats was
determined using a noninvasive tail-cuﬀ monitor (MK2000;
Muromachi Kikai Co. Ltd, Tokyo, Japan). Values are pre-
sented as the mean of three measurements.
2.4. Preparation of Isolated Aortic Rings. The application of
aortic ring isolated from SHR was employed in the present
study.Eachratwassacriﬁcedbymeansofdecapitationunder
anesthesia with pentobarbital (50mgkg−1). As described in
our previous study [9], we rapidly removed the thoracic
aortae and placed them in oxygenated Krebs buﬀer (95% O2,
5% CO2). After the fat and connective tissue were gently dis-
sected, the aortae were cut into ring segments approximately
3-mm long. The rings were then mounted in 37
◦Co r g a n
baths ﬁlled with 10mL of oxygenated Krebs buﬀer (95%
O2,5 %C O 2) containing 135mmoll−1 NaCl, 5mmoll−1
KCl, 2.5mmoll−1 CaCl2, 1.3mmoll−1 MgSO4, 1.2mmoll−1
KH2PO4, 20mmoll−1 NaHCO3 and 10mmoll−1 d-glucose
(pH 7.4).
Each preparation was connected to strain gauges (FT03;
Grass Instrument Co., Quincy, MA, USA). Isometric tension
was recorded by using chart software (MLS023, Powerlab;
AD Instruments Pty Ltd, Bella Vista, New South Wales,
Australia). The rings were mounted and allowed to stabilize
for 2h. The preparation was then gradually stretched to
achieve an optimal resting tension of 1g.
2.5. Removal of Endothelium. To preclude the possible role
of endothelium in the vasodilatation of tanshinone IIA, the
tests were conducted in endothelium-denuded preparations.
The endothelium was removed by gently rubbing against
the teeth of a pair of forceps. Success of the removal
of endothelium was characterized using the failure of
10µmoll−1 acetylcholine to relax the rings precontracted
with 10nmoll−1 phenylephrine.
2.6. Vasodilatation Induced by Tanshinone IIA. After stabi-
lization of resting tension, phenylephrine (10nmoll−1)o r
potassium chloride (KCl) (40mmoll−1) in distilled water
was added into bathing buﬀer to induce a rapid increase
in vascular tone followed by stable vasoconstriction (tonic
contraction). The treatment group was given tanshinone
IIA (0.1–10µmoll−1) to observe the decrease in tonic
contraction (vasodilatation). Relaxation was expressed as
the percentage decrease of maximal tonic contraction.
Concentration-relaxation curves were generated in cumula-
tive fashion.
2.7. Eﬀect of K+ Channel Blockers on the Vasodilatation
of Tanshinone IIA. After the resting tension became sta-
bilized, phenylephrine (10nmoll−1) or KCl (40mmoll−1)
was administered into bathing buﬀer to induce an increase
of vascular tone followed by the stable vasoconstriction
(tonic contraction). Then, testing groups were treated with
tanshinone IIA to produce a lowering of tonic contraction
that was indicated as vasodilatation in the present study.
The K+ channel blockers, including glibenclamide, apamin,
charybdotoxin, barium chloride and 4-aminopyridine, dis-
solved in distilled water, were administered at the eﬀective
concentration for 30min before tanshinone IIA was added
and the vasodilatation of tanshinone IIA was compared with
samples treated same volume of vehicle used to dissolve
the testing blockers [9, 10]. The relaxation was calculatedEvidence-Based Complementary and Alternative Medicine 3
from the decrease of tonic vasoconstriction induced by
phenylephrine or KCl and expressed as the percentage of
maximal contraction. Concentration-relaxation curves were
generated in a cumulative fashion.
2.8. Measurement of [Ca2+]i Concentration in A7r5 Cells
with Fura-2. The A7r5 line of rat aortic smooth muscle
cells obtained from the Food Industry Institute (Hsin-Chu,
Taiwan) were incubated in DMEM containing 10% (V V−1)
fetal bovine serum with fura-2 (5µmoll−1) in the dark at
room temperature for 30min. Then, the cells were gently
washed twice with Ca2+-free physiologic salt solution after
they were centrifuged at 3000rpm for 7min and kept in
the same solution containing Ca2+. The physiologic salt
solution contained 140mmoll−1 NaCl, 5.9mmoll−1 KCl,
1.2mmoll−1 NaH2PO4, 5mmoll−1 NaHCO3, 1.4mmoll−1
MgCl2, 1.8mmoll−1 CaCl2 and 11.5mmoll−1 glucose. The
cells were maintained on ice until the [Ca2+]i was measured.
The [Ca2+]i was measured by using an emission wave-
length of 520nm and alternating excitatory wavelengths of
340 and 380nm (F-2000 spectrophotometer; Hitachi, Tokyo,
Japan).Usingexternalcalibration,wethencalculated[Ca2+]i
according to the equation [Ca2+]i = [(R−Rmin)/(Rmax −R)×
(Sf2/Sb2) × Kd], where R is the ﬂuorescence intensity of the
Ca2+-sensitive dye fura-2 at excitation wavelengths of 340
and380nm,Rmin istheminimumﬂuorescenceratioofabout
0.768 and Rmax is the maximum ﬂuorescence ratio of about
35.1. The coeﬃcient Sf2 indicates the free dye measured at
wavelength of 380nm and Sb2 indicates Ca2+-bound dye at
380nm. According to experimental data, Sf2/Sb2 f o rf u r a - 2i s
about 15.3. Kd is the eﬀective dissociation constant of fura-2,
which was about 135nmoll−1.
The change of [Ca2+]i in response to phenylephrine or
KCl was evaluated by using normal physiologic salt solution
containing Ca2+. Pretreatment of tanshinone IIA was carried
out to identify its antagonism of Ca2+. We administered
the K+ channel blockers, then added tanshinone IIA to
determine this inhibition of [Ca2+]i by tanshinone IIA that
involved the opening of K+ channels.
2.9. Statistical Analysis. Data were expressed as the mean
± SD for the number (n) of animals in each group as
indicated in the tables and ﬁgures. Statistical diﬀerences
among groups were determined by using two-way repeated-
measure ANOVA. Dunnett range post-hoc comparisons
were used to determine the source of signiﬁcant diﬀerences
where appropriate P value <. 05 was considered statistically
signiﬁcant.
3. Results
3.1. Danshen-Induced Modulation of SBP in Rats. Ad o s e -
dependent decrease of SBP in SHR received an i.p. injection
ofdanshenwasshowninFigure 1;themaximaleﬀect(20.1±
3.1%) was achieved by 60-min treatment with danshen at
10mgkg−1. The eﬀect of danshen on the reduction of SBP
was maintained for 150min (Figure 1). No change of SBP
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Figure 1: Changes of SBP in WKY or SHR receiving an i.p. of
danshen or vehicle at various times. Data were expressed as the
mean ± SD for seven rats in each group. ∗∗P<. 01 versus data from
vehicle-treated WKY. #P<. 05 and ##P<. 01 versus vehicle-treated
SHR, respectively.
was observed in WKY receiving the similar administration
of danshen at 10mgkg−1 for 60min (Figure 1).
3.2. Tanshinone IIA-Induced Modulation of SBP in SHR.
After treatment with tanshinone IIA, SBP was noticeably
reduced in SHR; a 60-min treatment with tanshinone
IIA at the oral dosage of 60mgkg−1 signiﬁcantly lowered
SBP in SHR (Figure 2) However, administering WKY with
tanshinone IIA (60mgkg−1) for 60min failed to modify the
SBP (Figure 2).
3.3. Tanshinone IIA-Induced Changes on Vascular Tone.
The SHR aortic ring strips strongly contracted after an
initial application of phenylephrine (10 nmoll−1)o rK C l( 4 0
mmoll−1)(Figure 3).AlthoughtanshinoneIIAdidnotinﬂu-
ence resting vascular tone, it dilated both phenylephrine-
and KCl-induced contractions in a concentration-dependent
manner. At the maximal concentration, tanshinone IIA
(10µmoll−1) signiﬁcantly attenuated the tonic contraction
of SHR aortic rings induced by phenylephrine (10nmoll−1)
to 24.9 ± 5.2% of the maximal contraction (Figure 3).
Also, the eﬀect of tanshinone IIA (10µmoll−1)o nK C l
(40mmoll−1)-induced tonic vasoconstriction approached
28.3 ±5.4% of the maximal contraction (Figure 3).
3.4. Role of Endothelium in Tanshinone IIA-Induced Relax-
ation. No diﬀerence (P>. 05) can be observed regarding
the relaxing eﬀect of tanshinone IIA (10µmoll−1)o n
phenylephrine (10nmoll−1)-induced tonic vasoconstriction
between SHR aortic rings with or without functional
endothelium (Figure 4).4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Changes of SBP in WKY or SHR receiving an oral
administration of tanshinone IIA or vehicle for 60min. Data were
expressed as the mean ± SD for seven rats in each group. ∗∗P<. 01
versusdatafromvehicle-treated WKY. #P<. 05and ##P<. 01versus
vehicle-treated SHR, respectively.
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Figure 3: Concentration-dependent relaxing action of tanshinone
IIA in the isolated SHR aortic rings contracted with phenylephrine
(10nmoll−1)o rK C l( 4 0 m m o l l −1). The preparation of isolated
aortic rings from male SHR was described in Section 2. Data (mean
±SD)indicatethepercentagedilationsofthemaximalcontractions
in eight experiments. ∗P<. 05 and ∗∗P<. 01 versus vehicle-treated
group in each group.
3.5. Role of K+ Channels in Tanshinone IIA-Induced Vasodi-
latation. In the presence of glibenclamide (1–100µmoll−1),
the blockers speciﬁc to ATP-sensitive K+ (KATP) channel,
the relaxing eﬀect of tanshinone IIA on tonic contraction
in phenylephrine (10nmoll−1)-precontracted SHR aortic
ringswassigniﬁcantlyreducedinaconcentration-dependent
0.1 1 10
Tanshinone IIA (µmol l−1)
C
o
n
t
r
a
c
t
i
o
n
f
o
r
c
e
(
%
)
0
20
40
60
80
100
Vehicle
+ endothelium
− endothelium
Figure 4: Comparison of the dilative eﬀect of tanshinone IIA on
vasoconstriction induced by phenylephrine (10nmoll−1)i nt h e
presence of endothelium (closed circle) or not (open circle). +,
presence; −, absence. The preparation of isolated aortic rings from
male SHR was described in Section 2. Data (mean ± SD) were
obtained from eight experiments.
manner (Table 1). The vasodilatation due to tanshinone IIA
in KCl (40mmoll−1)-pretreated SHR aortic rings was also
attenuated under glibenclamide treatment in a similar way
(Table 1).
However,inthepresenceofablockerspeciﬁctotheCa2+-
sensitive small conductance K+ (SKCa) channel (0.1µmoll−1
apamin), the relaxing eﬀect of tanshinone IIA on tonic
contraction of phenylephrine (10nmoll−1) remained at
25.1 ± 4.6% of the maximal contraction. Also, charybdo-
toxin (0.1µmoll−1), the large-conductance Ca2+-activated
K+ channel (LKCa channel) blocker, failed to modify the
relaxation of tanshinone IIA, with a result of 23.7 ±
5.2% of phenylephrine (10nmoll−1)-induced tonic con-
traction. Moreover, inhibition of inward rectiﬁer K+ chan-
nel (KIR channel) with barium chloride (10µmoll−1)o r
blockade of voltage-dependent K+ channel (KV channel)
with 4-aminopyridine (1mmoll−1), the relaxing eﬀect of
tanshinone IIA on tonic contraction of phenylephrine
(10nmoll−1)wasstill26.4±4.2%or24.4±6.5%,respectively
(Table 1).
Similarly, the vasodilation due to tanshinone IIA in KCl
(40mmoll−1)-pretreated SHR aortic rings was not reserved
under apamin treatment (Table 1). Also, blockade of LKCa,
KIR or KV channel by other speciﬁc inhibitors failed
to modify the vasodilatation of tanshinone IIA on KCl
(40mmoll−1)-induced tonic contraction (Table 1).
3.6. Role of K+ Channels in the Inhibitory Eﬀect of
Tanshinone IIA on Intracellular Ca2+ Concentrations in
A7r5 Cells. In Ca2+-containing medium, phenylephrine
(10nmoll−1) increased [Ca2+]i in A7r5 cells from 214.7 ±
34.2 to 440.2 ± 29.3nmoll −1 (Figure 5). Tanshinone IIAEvidence-Based Complementary and Alternative Medicine 5
Table 1: Inhibitory eﬀect of K+ channel blockers on the vasodilatation of tanshinone IIA in isolated SHR aortic rings contracted with
phenylephrine or KCL
a.
Contraction force (%)
Phenylephrine (10nmoll−1) KCl (40mmoll−1)
Vehicle Tanshinone IIA (10µmoll−1) Vehicle Tanshinone IIA (10µmoll−1)
Basal 100## 24.9 ±5.1
∗∗ 100## 28.3 ±4.8
∗∗
Glibenclamide (µmoll−1)
19 9 .2 ±4.9## 59.3 ±7.1
∗∗ 98.6 ±5.8## 53.5 ±4.9
∗∗
10 98.8 ±6.1## 73.3 ±5.9
∗,# 98.2 ±4.9## 78.6 ±6.4
∗,#
100 98.6 ±5.6## 87.4 ±6.7## 97.9 ±6.3## 90.3 ±5.6##
Apamin (0.1µmoll−1)9 9 .2 ±3.7## 27.6 ±4.7
∗∗ 98.4 ±4.7## 29.5 ±5.7
∗∗
Charybdotoxin (0.1µmoll−1)9 8 .7 ±4.1## 26.4 ±5.1
∗∗ 98.6 ±5.3## 31.2 ±4.9
∗∗
Barium chloride (10µmoll−1)9 9 .1 ±5.6## 28.2 ±3.9
∗∗ 97.8 ±4.6## 30.5 ±5.1
∗∗
4-Aminopyridine (1mmoll−1)9 8 .6 ±3.9## 27.9 ±4.2
∗∗ 98.5 ±6.9## 32.5 ±6.1
∗∗
aThe preparation of isolated aortic rings from male SHR was described in Section 2. Data (mean ± SD) indicate the percentage dilations of the maximal
contractions in eight experiments. Data from phenylephrine (10nmoll−1)- or KCl (40mmoll−1)-treated sample without K+ channel blockers treatment was
served as basal level in each group. ∗P<. 05 and ∗P<. 01 versus basal level obtained from samples treated with the same volume of vehicle to dissolve testing
K+ channel blockers in each group. #P<. 05 and ##P<. 01 versus value from sample received tanshinone IIA treatment in the absence of K+ channel blockers
in each group.
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Figure 5: Eﬀect of tanshinone IIA on the phenylephrine
(10nmoll−1) or KCl (40mmoll−1)-induced increase of [Ca
2+]i in
A7r5 line of rat aortic smooth muscle cells. Changes of [Ca
2+]i in
A7r5 cells were measured by fura-2 as described in Section 2.T h e
[Ca
2+]i obtained from A7r5 cells without treatment was 212.6 ±
32.4nmoll −1. The data (mean ± SD) were obtained from six
experiments.
attenuated this increase of [Ca2+]i induced by phenyle-
phrine (10nmoll−1) in a concentration-dependent manner;
the maximal inhibitory activity of tanshinone IIA was
observed at 10µmoll−1 (Figure 5). However, glibenclamide
(1–100µmoll−1) reversed the inhibitory eﬀect of tanshinone
IIA (10µmoll−1)o n[ C a 2+]i induced by phenylephrine
(10nmoll−1)( Table 2).
Also, KCl (40mmoll−1) increased [Ca2+]i in A7r5 cells to
428.6±27.4nmoll −1 inCa2+-containingmedium(Figure 5).
Tanshinone IIA similarly inhibited the elevation of [Ca2+]i
induced by KCl (40mmoll−1) in a concentration-dependent
manner (0.1–10µmoll−1) parallel to its eﬀects against the
action of phenylephrine (10nmoll−1)( Figure 5), though
glibenclamide markedly attenuated this eﬀect (Table 2).
However, neither apamin (0.1µmoll−1)n o rc h a r y b d o -
toxin (0.1µmoll−1) modify the inhibition of tanshinone IIA
(10µmoll−1)-induced changes in [Ca2+]i in A7r5 cells; the
rise of [Ca2+]i in A7r5 cells by phenylephrine (10nmoll−1)
orKCl(40mmoll−1)wasnotchangedsigniﬁcantly(Table 2).
Also, barium chloride (10µmoll−1) or 4-aminopyridine
(1mmoll−1) did not inﬂuence the inhibitory eﬀect of
tanshinone IIA on [Ca2+]i in phenylephrine (10nmoll−1)-
or KCl (40mmoll−1)-treated A7r5 cells (Table 2).
4. Discussion
Clinically, the application of danshen is clearly studied and
intravenous injection danshen containing 40mg of tanshi-
none IIA twice a day for 28 days is eﬀective to improve the
neurological functions in patients suﬀered with strokes [5].
Also, oral administration of tanshinone IIA at 1g daily doses
is helpful to cure the stroke symptoms [5]. Danshen and the
contained activate compounds, tanshinone IIA, may poten-
tially provide advantage on the control of cardiovascular
diseases in clinic. Tanshinone IIA has been introduced as the
most abundant and representative principle of tanshinone
derivatives [11], while tanshinone IIA is rapidly cleared
by hepatic metabolism and cryptotanshinone is converted
into tanshinone IIA as a precursor in the liver [12]. In
the present study, we found that danshen and tanshinone
IIA markedly decreased blood pressure in hypertensive rats,
but the beneﬁt eﬀects on the regulation of blood pressure
were not exited in the normotensive rats. Thus, we used
tanshinoneIIAtoevaluatethevasodilativeactivityinisolated
aorta to support the blood pressure lowering the eﬃcacy
of danshen in hypertensive rats, mainly mediated by the
action of tanshinone IIA. Tanshinone IIA as the active6 Evidence-Based Complementary and Alternative Medicine
Table 2: Eﬀect of K+ channel blockers on the inhibition of tanshinone IIA-induced changes in [Ca
2+]i in A7r5 cells
a.
[Ca
2+]i (nmoll−1)
Phenylephrine (10nmoll−1) KCl (40mmoll−1)
Vehicle Tanshinone IIA (10µmoll−1) Vehicle Tanshinone IIA (10µmoll−1)
Basal 440.2 ±29.3## 256.4 ±32.5
∗∗ 423.7 ±32.4## 246.5 ±27.6
∗∗
Glibenclamide (µmoll−1)
1 451.3 ±35.7## 292.1 ±27.6
∗∗ 429.7 ±37.2## 283.5 ±29.8
∗∗
10 458.7 ±30.2## 371.6 ±23.7
∗,## 432.6 ±33.2## 386.2 ±31.5
∗,##
100 462.6 ±32.3## 405.3 ±31.4## 440.5 ±34.6## 418.6 ±28.6##
Apamin (0.1µmoll−1) 459.5 ±39.2## 264.8 ±28.4
∗∗ 439.8 ±29.7## 254.3 ±27.2
∗∗
Charybdotoxin (0.1µmoll−1) 460.3 ±34.2## 257.2 ±26.7
∗∗ 441.2 ±31.4## 252.9 ±30.6
∗∗
Barium chloride (10µmoll−1) 456.7 ±33.9## 270.7 ±32.4
∗∗ 436.5 ±28.6## 261.7 ±25.9
∗∗
4-Aminopyridine (1mmoll−1) 462.5 ±30.1## 262.3 ±34.1
∗∗ 443.8 ±32.5## 258.3 ±28.6
∗∗
aData (mean ± SD) were obtained from six experiments. The [Ca2+]i obtained from A7r5 cells without any treatment was 214.7 ± 34.2nmol l−1.D a t af r o m
phenylephrine (10nmoll−1)- or KCl (40mmoll−1)-treated cells without K+ channel blockers treatment were served as basal level in each group. ∗P<. 05
and ∗∗P<. 01 versus basal level obtained from cells treated with the same volume of vehicle to dissolve testing K+ channel blockers in each group. #P<. 05
and ##P<. 01 versus value from cells received tanshinone IIA treatment in the absence of K+ channel blockers in each group.
ingredient in danshen for cardiovascular diseases was further
supported by ﬁnding that phenylephrine- or KCl-induced
tonic contraction in aortic ring prepared from hypertensive
rats was alleviated by tanshinone IIA. Further research seems
essentialtounderstandtheactionmechanismsoftanshinone
IIA for aortic relaxation.
Role of the endothelium in controlling vascular contrac-
tility is well established and dysfunction of arterial tone is
believed to be due to abnormal endothelial function and/or
reduced nitric oxide (NO) in vascular disease [13, 14]. It
has been documented that danshen acts partially through
endothelial nitric oxide synthase-signaling mechanisms to
induce vasodilation and reduce blood pressure in hyperten-
sive hamsters [15]. However, vasodilatation of tanshinone
IIA remained produced in the absence of endothelium; the
endothelium-dependent NO-mediated vasodilation seems
unlikely to be involved in the antihypertensive action of tan-
shinone IIA. In general, an increase of [Ca2+]i is considered
as the major event of contraction in smooth muscle cells;
blockade of Ca2+ channels is the most common factor in
antihypertensive or vasodilative eﬀects [16]. We observed
that tanshinone IIA reduced phenylephrine- or KCl-induced
elevation of [Ca2+]i in cultured aortic smooth muscle cells,
indicating that reduction in [Ca2+]i might be related to the
vasodilative eﬀect of tanshinone IIA.
It is well known that membrane potential is a major
determinant of vascular tone and K+ channels play an
important role in the regulation of membrane potential
in vascular smooth muscle [8]. Changes in the activity
of K+ channels in vascular smooth muscle cell to elicit
hyperpolarizationandtherebyadeclinein[Ca2+]i mayresult
in vasodilatation [8, 16]. Therefore, we investigated the role
of K+ channel in tanshinone IIA-induced vasorelaxation.
The family of K+ channels is at least ﬁve well-
characterized members; the ATP-sensitive K channel is likely
to be a temporarily activated K+ channel that may inﬂuence
the [Ca2+]i related to the regulation of vascular tone in
vascular smooth muscle [8, 17]. It has been documented that
KCl at the concentration <50mmoll−1 did not depolarize
the membrane via opening of ATP-sensitive K+ channels
[18]. Actually, we used KCl at 40mmoll−1 to depolarize the
membrane of A7r5 cells and it is tanshinone IIA sensitive.
We then investigated the role of K+ channels in the action
of tanshinone IIA using pharmacologic blockers. In the
presence of eﬀective concentration of glibenclamide, the
well-known ATP-sensitive channel blocker [18], the ability
of tanshinone IIA to relax tonic contraction of isolated SHR
aortic rings was ablated. Glibenclamide also blunted the
decrease of [Ca2+]i due to tanshinone IIA in phenylephrine-
or KCl-pretreated A7r5 cells. However, apamin (SKCa chan-
nel blocker), charybdotoxin (LKCa channel blocker), barium
chloride (KIR channel blocker) and 4-aminopyridine (KV
channel blocker) were unable to interfere the ability of
tanshinone IIA to relax tonic contraction of aortic rings
isolated from SHR [13, 19, 20]; these inhibitors also failed
to modify the inhibitory eﬀect of tanshinone IIA on the
elevation of [Ca2+]i induced by phenylephrine or KCl. Thus,
the eﬀect of tanshinone IIA on vasodilatation is not expected
to be related to SKCa,L K Ca,K IR or KV channels; selective
opening of ATP-sensitive K+ channels canthus beconsidered
for the action of tanshinone IIA regarding the reduction
of [Ca2+]i to produce vasodilatation. Thus, it could be
speculatedthattanshinoneIIAposestheabilitytoopenATP-
sensitive K+ channels, which in turn leads to diﬀusion of K+
ions out of the vascular smooth muscle cells, then causes
membrane hyperpolarization to close voltage-gated Ca2+
channels, thus resulting in decreased [Ca2+]i,a n du l t i m a t e l y
leads to vasodilatation (Figure 6).
In fact, glibenclamide attenuated but did not abolish
the action of tanshinone IIA. Activation of ATP-sensitive
K+ channels appeared to be involved, cannot account
entirely for the vasodilative action of tanshinones. The
increase in [Ca2+]i reﬂects both the inﬂux of Ca2+ and the
release of Ca2+ from subcellular stores [21]. It has been
demonstrated that the relaxation eﬀects of danshen and its
lipid-soluble components (tanshinone I, tanshinone II(A),Evidence-Based Complementary and Alternative Medicine 7
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Figure 6: Schematic mechanisms for the induction of vasodilata-
tion by tanshinone IIA.
cryptotanshinone, dihydroisotanshinone I) and the water-
soluble compounds (danshensu and salvianolic acid B) on
the isolated rat femoral artery were produced by inhibition
of Ca2+ inﬂux while a small component was mediated by
the opening of K+ channels [22]. Also, sodium pumping or
a pH-sensitive twin-pore domain K+ channel contributes in
the membrane hyperpolarization [23, 24]. Therefore, other
mechanisms responsible for tanshinone-induced lowering
of [Ca2+]i in addition to the opening of ATP-sensitive K+
channel should be considered.
Nonetheless, it has been indicated that distribution
and/or sensitivity of ATP-sensitive K+ channel increased in
the hypertensive state to result in an augmented relaxation
to ATP-sensitive K+ channel opener which may be one of
the compensatory mechanisms to maintain vasorelaxation
in disordered state where endothelial function is impaired
[25]. Also, vasorelaxation in response to ATP-sensitive K+
channel opener was augmented in arteries from hypertensive
rats comparing to those from normotensive rats [7]. In the
present study, tanshinone IIA did not inﬂuence the resting
vasculartonebutreducedthevasoconstrictiononly.Also,the
chemical structure of tanshinone IIA is diﬀerent with cat-
echolamine; mediation of sympathetic nervous parameters
in this action of tanshinone IIA could be ruled out. This is
helpful to explain why tanshinone IIA lowered BP in SHR
but not in WKY.
It has been indicated that tanshinone derivatives includ-
ing cryptotanshinone and 15,16-dihydrotanshinone I are the
important constituents for the use of danshen in inﬂamma-
tory conditions [26]. Inhibition of osteoclast diﬀerentiation
by available tanshinone such as diterpenoids, tanshinone I,
tanshinone IIA, cryptotanshinone and dihydrotanshinone
has also been demonstrated [27]. However, the evidence of
active ingredients for the eﬃcacy of danshen in cardiovas-
cular disease has some limitations. Our results provided new
insightfortheapplicationoftanshinoneIIAinopeningATP-
sensitive K+ channels, an eﬀect which might be useful for
the understanding of action and mechanisms of danshen
in producing aortic relaxation. Indeed, ATP-sensitive K+
channel openers are vasodilators used in clinic [28]. The
herbal principle, such as tetramethylpyrazine, an active
ingredient found in the herb Ligusticum chuanxiong Hort.
(Umbelliferae), is similar to tanshinone IIA acting as the
ATP-sensitive K+ channel opener [9, 10]. Thus, herbal
products responsible for the opening of ATP-sensitive K+
channels might eventually be useful in the handling of
hypertension and/or cardiovascular disorders.
In conclusion, the opening of ATP-sensitive K+ channels
can be considered as one of the mechanisms for tanshinone
IIA that reduced [Ca2+]i to induce vasodilatation.
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